Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO

NCT00645606 is registered in ClinicalTrials.gov with University Hospital, Tours as lead sponsor.

NCT NCT00645606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00645606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO
Lead sponsor
University Hospital, Tours
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2007
Completion date
July 31, 2017
Enrollment
542 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia